[go: up one dir, main page]

WO2001021620A3 - Derives d'amine - Google Patents

Derives d'amine Download PDF

Info

Publication number
WO2001021620A3
WO2001021620A3 PCT/EP2000/008256 EP0008256W WO0121620A3 WO 2001021620 A3 WO2001021620 A3 WO 2001021620A3 EP 0008256 W EP0008256 W EP 0008256W WO 0121620 A3 WO0121620 A3 WO 0121620A3
Authority
WO
WIPO (PCT)
Prior art keywords
amine derivatives
thieno
pyrimidines
benzo
ring
Prior art date
Application number
PCT/EP2000/008256
Other languages
German (de)
English (en)
Other versions
WO2001021620A2 (fr
Inventor
Volker Eiermann
Rochus Jonas
Original Assignee
Merck Patent Gmbh
Volker Eiermann
Rochus Jonas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Volker Eiermann, Rochus Jonas filed Critical Merck Patent Gmbh
Priority to CA002387520A priority Critical patent/CA2387520A1/fr
Priority to AU74127/00A priority patent/AU7412700A/en
Priority to PL00353319A priority patent/PL353319A1/xx
Priority to KR1020027003415A priority patent/KR20020027652A/ko
Priority to BR0014052-0A priority patent/BR0014052A/pt
Priority to JP2001524996A priority patent/JP2003509511A/ja
Priority to EP00962374A priority patent/EP1212329A2/fr
Publication of WO2001021620A2 publication Critical patent/WO2001021620A2/fr
Publication of WO2001021620A3 publication Critical patent/WO2001021620A3/fr
Priority to NO20021310A priority patent/NO20021310L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des dérivés d'amine de formule (I), ainsi que leur sels et solvates physiologiquement acceptables. Dans la formule (I): R?1, R2, R8, R9, R10, R11¿, Q, X, Y, Z, r, les composés cycliques A et C ont les significations indiquées dans la revendication (1). Ces composés permettent l'inhibition de la phosphodiestérase V et peuvent être utilisés pour le traitement de troubles du système cardio-vasculaire et pour le traitement et/ou la thérapie de troubles de puissance.
PCT/EP2000/008256 1999-09-17 2000-08-24 Derives d'amine WO2001021620A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002387520A CA2387520A1 (fr) 1999-09-17 2000-08-24 Derives d'amine
AU74127/00A AU7412700A (en) 1999-09-17 2000-08-24 Amine derivatives
PL00353319A PL353319A1 (en) 1999-09-17 2000-08-24 Amine derivatives of benzo-4,5-thieno-2,3-d pyrimidines
KR1020027003415A KR20020027652A (ko) 1999-09-17 2000-08-24 아민 유도체
BR0014052-0A BR0014052A (pt) 1999-09-17 2000-08-24 Derivados de aminas
JP2001524996A JP2003509511A (ja) 1999-09-17 2000-08-24 アミン誘導体
EP00962374A EP1212329A2 (fr) 1999-09-17 2000-08-24 Derives d'amines de benzo[4,5]thieno[2,3-d]pyrimidine
NO20021310A NO20021310L (no) 1999-09-17 2002-03-15 Aminderivater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19944604.0 1999-09-17
DE19944604A DE19944604A1 (de) 1999-09-17 1999-09-17 Aminderivate

Publications (2)

Publication Number Publication Date
WO2001021620A2 WO2001021620A2 (fr) 2001-03-29
WO2001021620A3 true WO2001021620A3 (fr) 2001-11-01

Family

ID=7922374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/008256 WO2001021620A2 (fr) 1999-09-17 2000-08-24 Derives d'amine

Country Status (11)

Country Link
EP (1) EP1212329A2 (fr)
JP (1) JP2003509511A (fr)
KR (1) KR20020027652A (fr)
AU (1) AU7412700A (fr)
BR (1) BR0014052A (fr)
CA (1) CA2387520A1 (fr)
CZ (1) CZ2002817A3 (fr)
DE (1) DE19944604A1 (fr)
NO (1) NO20021310L (fr)
PL (1) PL353319A1 (fr)
WO (1) WO2001021620A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10148883A1 (de) 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
WO2003035653A1 (fr) * 2001-10-26 2003-05-01 Nippon Soda Co.,Ltd. Compose pyridothienopyrimidine et son sel
AR059901A1 (es) * 2006-03-20 2008-05-07 Bayer Pharmaceuticals Corp Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1603313A (en) * 1964-01-15 1971-04-05 Thieno 3 2-d pyrimidines
EP0728759A1 (fr) * 1995-02-24 1996-08-28 Ono Pharmaceutical Co., Ltd. Composés hétérocycliques
WO1998017668A1 (fr) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidines a effet inhibiteur de la phosphodiesterase v
US5948911A (en) * 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
WO1999055708A1 (fr) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidines condensees a effet inhibiteur de la phosphodiesterase v
WO2000059912A1 (fr) * 1999-03-30 2000-10-12 Nippon Soda Co., Ltd. Composes de thienopyrimidine et leurs sels, et procede de preparation desdits composes et sels
WO2000078767A1 (fr) * 1999-06-19 2000-12-28 Merck Patent Gmbh Thienopyrimidines utilisees comme inhibiteurs de phosphodiesterase

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1603313A (en) * 1964-01-15 1971-04-05 Thieno 3 2-d pyrimidines
EP0728759A1 (fr) * 1995-02-24 1996-08-28 Ono Pharmaceutical Co., Ltd. Composés hétérocycliques
WO1998017668A1 (fr) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidines a effet inhibiteur de la phosphodiesterase v
WO1999055708A1 (fr) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidines condensees a effet inhibiteur de la phosphodiesterase v
US5948911A (en) * 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
WO2000059912A1 (fr) * 1999-03-30 2000-10-12 Nippon Soda Co., Ltd. Composes de thienopyrimidine et leurs sels, et procede de preparation desdits composes et sels
WO2000078767A1 (fr) * 1999-06-19 2000-12-28 Merck Patent Gmbh Thienopyrimidines utilisees comme inhibiteurs de phosphodiesterase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLINA, PEDRO ET AL: "Iminophosphorane-mediated bispyrido annulation onto five-membered rings. X-ray crystal structure of 6,7-dibenzylamino-13-methoxymethyl- 13H-diquino[4,3-b:3',4'-d]pyrrole.acetonitrile complex", TETRAHEDRON (1995), 51(44), 12127-42, XP002164407 *

Also Published As

Publication number Publication date
BR0014052A (pt) 2002-05-21
WO2001021620A2 (fr) 2001-03-29
NO20021310D0 (no) 2002-03-15
AU7412700A (en) 2001-04-24
DE19944604A1 (de) 2001-03-22
JP2003509511A (ja) 2003-03-11
PL353319A1 (en) 2003-11-17
CZ2002817A3 (cs) 2002-06-12
CA2387520A1 (fr) 2001-03-29
KR20020027652A (ko) 2002-04-13
NO20021310L (no) 2002-03-15
EP1212329A2 (fr) 2002-06-12

Similar Documents

Publication Publication Date Title
HK1046527A1 (zh) 金剛烷衍生物
BG106586A (en) Pyrazolopyramidines as therapeutic agents
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
GEP20022653B (en) Processes and Intermediates for Preparing Anti-Cancer Compounds
MY112102A (en) Therapeutic heterocycles.
BG106003A (en) New n-cyanomethylamides and compositions as protease inhibitors
GEP20053476B (en) 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
GEP20043324B (en) Purine Derivatives
WO2001046200A8 (fr) Nouveaux derives de piperidine et de piperazine
HK1042091A1 (zh) 金剛烷衍生物
AP9701041A0 (en) Pyridylpyrrole compounds.
MY125978A (en) Admantane derivatives
IL165696A0 (en) Substituted 1,3-diphenykprop-2-en-1-one derivatives and preparation and uses thereof
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
WO2003048164A3 (fr) Antagonistes du recepteur a2a de l'adenosine
AU3850600A (en) Dalda analogs and their use
GB9305295D0 (en) Therapeutic compounds
WO2002018379A3 (fr) 7-oxo pyridopyrimidines
GEP20053617B (en) Bridged Piperazine Derivatives
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
WO2001018004A3 (fr) PYRAZOLO[4,3-d]PYRIMIDINES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000962374

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2002-817

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 3332002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020027003415

Country of ref document: KR

Ref document number: PA/A/2002/002866

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 524996

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2387520

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/469/KOL

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 1020027003415

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 74127/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200200344

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2002 2002109469

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000962374

Country of ref document: EP

Ref document number: PV2002-817

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10088344

Country of ref document: US

WWR Wipo information: refused in national office

Ref document number: PV2002-817

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000962374

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)